Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.,European Journal of Neurology

当前位置： X-MOL 学术 › Eur. J. Neurol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
European Journal of Neurology ( IF 4.5 ) Pub Date : 2020-05-17 , DOI: 10.1111/ene.14324
G Boffa ₁ , C Lapucci ₁ , E Sbragia ₁ , R Varaldo ₂ , A M Raiola ₂ , D Currò ₃ , L Roccatagliata _{4,

5} , E Capello ₆ , A Laroni _{1,

6} , M Mikulska _{5,

7} , F Gualandi ₂ , A Uccelli _{1,

6} , E Angelucci ₂ , G L Mancardi _{1,

8} , M Inglese _{1,

6}

Affiliation

The best therapeutic approach for aggressive relapsing–remitting multiple sclerosis remains unknown. The objective was to compare the efficacy and safety of autologous haematopoietic stem cell transplantation (aHSCT) and alemtuzumab in aggressive relapsing–remitting multiple sclerosis.

中文翻译：